Toca 6 Clinical Trial

Enrollment Now Open for Patients with Metastatic Cancers, Including Colorectal, Pancreatic, Breast, Melanoma and Renal cancers.

Participation in a clinical trial is one possible option for people who have cancer. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.

Tocagen initiated a Phase 1b clinical trial in July 2016 for patients with metastatic colorectal, pancreatic, breast, lung, melanoma and renal cancers.

The trial will evaluate the safety, presence of Toca 511 genes in tumors of patients with widely disseminated disease, immunologic activity in blood and tumor and clinical activity such as tumor response and clinical benefit. Tocagen also plans, in this clinical trial, to evaluate Toca 511 & Toca FC in combination with one or more checkpoint inhibitors.

Please fill out the patient inquiry form to learn more about potential participation in the Toca 6 trial. A patient may qualify for this study if the patient:

  • has metastatic cancer: colorectal, breast, lung, pancreatic, renal or melanoma
  • is a candidate for biopsy or resection of at least one lesion
  • is between 18 years old and 90 years old

Currently, this study is being offered in the United States. View a list of participating sites.

  • Learn More About The Toca 6 Trial

  • (Last Name Optional)
  • Toca 6 is open for patients with metastatic cancers, including colorectal, pancreatic, breast, melanoma and renal cancers
    View a list of participating sites.
  • ABOUT YOUR DATA

    We collect information you submit via inquiry forms and store it within our database. This information may be accessed by us in the future to respond to you, or to provide you with information that we believe helps to fulfill your request, or that would be of interest based on the nature and/or methodology of your inquiry. We don’t sell or distribute for marketing purposes your private information.

Learn more about the study including a full list of entry criteria.

Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.